Ken Griffin is a billionaire hedge fund manager and serves as CEO to Citadel Advisors. According to Citadel's most recent 13F ...

Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...

On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

Jefferies analyst Keith Devas initiated coverage with a Buy rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target ...

On October 23, 2024, Johnson & Johnson (NYSE:JNJ), the world's largest and most diverse healthcare firm, filed its 10-Q ...

On Tuesday, Kenvue Inc (KVUE) stock saw a modest uptick, ending the day at $22.93 which represents a slight increase of $0.01 or 0.04% from the prior close of $22.92. The stock opened at $22.55 and ...

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Financial writer analyzes activist hedge fund CEO's call for Kenvue to revamp skincare, health, and beauty segments for ...

In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...